EP0734262A1

EP0734262A1 - Use of pentoxifyllin in the treatment of multiple sclerosis

Info

Publication number: EP0734262A1
Application number: EP95904491A
Authority: EP
Inventors: Peter Rieckmann
Original assignee: Dr Rentschler Arzneimittel GmbH and Co KG
Current assignee: Dr Rentschler & Co Medizin KG GmbH
Priority date: 1993-12-16
Filing date: 1994-12-16
Publication date: 1996-10-02
Also published as: FI962473A0; NO962503L; SK76696A3; FI962473A; NO962503D0; CZ170896A3; PL314588A1; JPH09506603A; WO1995016450A1; DE4343034C1; CA2176848A1

Abstract

The invention concerns the use of pentoxifyllin in the treatment of the stepwise advancing or chronically progressing form of multiple sclerosis. This use can be implemented alone or in combination with corticosteroids. The dose is 0.01 to 6.0 g/day, irrespective of the presence of corticosteroids.

Description

Use of pentoxifylline for the treatment of multiple sclerosis

The invention relates to the use of pentoxifylline for the treatment of the relapsing or chronically progressive form of multiple sclerosis.

Multiple sclerosis (MS) is one of the most common neurological diseases in our latitudes. It usually begins in early adulthood and can be chronically progressive or relapsing. Their exact mechanism of origin is not yet known. However, both genetic dispositions and environmental factors seem to play a role.

The well-known clinical picture of MS includes the disseminated foci of desmarking in the patient's central nervous system (CNS). This demyelination spreads unsystematically in batches in the CNS and leads to the so-called flare-ups of nervous disorders that characterize the symptoms of the disease.

In many cases there is also a definable, new disease stage of steady progression. It is assumed that pathomechanisms other than the progressive demyelination also play a role in this late stage.

So far, the disease can only be treated symptomatically when the relapses occur with new neurological symptoms by administering corticosteroids (1 g / day iv over 3 days), which leads to a shortening of the relapse duration. Due to the known, numerous and serious side effects of the corticoids, however, preventive continuous therapy cannot be carried out with them. In addition, the treatment of patients who also have other diseases to be influenced by corticosteroids, e.g. B. Type I diabetes mellitus, extremely difficult and risky. In order to avoid these disadvantages, various drug groups were examined for their effectiveness.

Studies on continuous therapy of MS with immunosuppressants such as azathioprine or cyclosporin A have been shown to have no effects on the course of the disease. In contrast, subcutaneous administration of interferon-beta was able to show a significant reduction in thrust for the first time. However, this application of interferon beta is difficult for the patient to handle, has numerous side effects and is very cost-intensive. In addition, interferon beta only works in those patients in whom the MS symptoms initially appear reluctantly.

It is therefore the object of the invention to provide a preparation for the therapy of MS which overcomes the disadvantages mentioned above.

The object on which the invention is based is surprisingly achieved by the use of pentoxifylline in the therapy of the batchwise or chronically progressive form of MS.

Pentoxifilyl (PTX) is known to first of all have a positive effect on the deformability of erythrocytes and leukocytes. It is therefore mainly used to improve the microcirculation in angiopathies (J. of Medicine, Vol. 10, No. 5, 1979) or in general in peripheral arterial circulatory disorders and immune disorders. Secondly, it is known that pentoxifilline reduces platelet aggregation, promotes the release of prostacyclin I, and lowers mitotic rates of lymphomas. It is therefore used to prevent metastasis and in lymphoma therapy (J. of Medicine, Vol. 15, No. 5 and 6, 1984). A further indication for this use of pentoxifylline is experimental peritonitis, the administration of which leads to significantly less abscess formation and fibrin deposition (Are. Sog. Vol. 120, pp. 1141-1144, 1985).

It has now been found that PTX, in addition to the previously known indications, is suitable for the treatment of multiple sclerosis, without the frequently occurring side effects associated with other therapies. In the course of an open therapy study, first experiences in relapsing treatment with pentoxifylline were found. Both the intravenous treatment (3 x 200 mg iv / day for 5 days) and the oral therapy (3 to 4 x 400 mg / day) showed a significant reduction in the duration of the relapse and an increase in the relapse-free interval.

The dose of pentoxifylline to be used is based on the general condition and the weight of the patient. It is generally 0.01 to 6 g / day, preferably 1 to 3 g / day and very particularly preferably 1.2 to 2.4 g / day. Based on kg of body weight, the concentrations used are 0.1 to 120 mg / (day kg), preferably 10 to 60 mg / (day kg) and very particularly preferably 12 to 48 mg / (day kg).

It was furthermore found that, in addition to the sole application of pentoxifylline, a combination with corticosteroids in the acute relapse treatment is indicated in a completely unexpected manner due to a surprising synergistic effect of both substances when administered together.

In addition to other therapeutically used corticosteroids, prednisone, prednisolone, prednisolone-21-acetate, prednylidene and methyl prednisone are particularly suitable. Methylprednisolone is preferably used.

The dosage is 0.01 to 10 mg / day, preferably 10 to 250 mg / day and very particularly preferably 100 to 200 mg / day. In single youngsters of mg per

-4 days and kg body weight, it is 10 to 20, preferably

0.1 to 2.5 and very particularly preferably 1 to 2 mg / (day kg).

When PTX and corticosteroids are combined in therapy, doses are preferably prepared which correspond to the doses most preferred, for example 1.2 mg / day PTX (16 mg / kg day PTX) orally and 500 mg / day Methylprednisolone (7 mg / kg day, iv) over 3 days. This amount is significantly lower than the doses previously administered in acute relapse therapy (1 g / day iv over 3 days). The lower doses significantly reduce the risk of a temporary diabetic metabolism, as is often observed with the previously used doses, with identical therapy success.

Of course, the doctor may, within his own discretion, deviate from the dosages given here.

The dose units of both the pure PTX preparations and the combinations with corticosteroids can be in the form of tablets, dragées, capsules or sustained-release formulas. When capsules are used, the capsule material takes on the function of the carrier and the contents, for . B. may be present as a powder, gel, emulsion, etc. However, it is particularly advantageous to prepare oral, sublingual and oral formulations with the active ingredient which contain the calculated amounts of the active ingredient together with the desired carrier. It is also possible to manufacture preparations for transdermal or parenteral (i.p., i.v., i.m., subcutaneous) injection of solutions or crystal suspensions as a depot preparation. Inhalation preparations (spray preparations) or suppositories can also be used.

All of the preparations mentioned can be produced by the known methods.

All pharmacologically usual materials can be used as carrier materials, auxiliaries and additives.

Possible dosages are 200, 400 or 600 mg PTX / tablet or 100 or 300 mg PTX / ampoule; for the corticosteroids 0.5 to 10 mg / tablet or 10 to 1000 mg / ampoule.

In combination preparations, 200 to 300 mg PTX and 0.5 to 10 mg corticoid / tablet or 100 to 150 mg PTX and 10 to 1000 mg corticoid / ampoule are used. Case studies

Example 1:

A female patient (42 years, 64 kg body weight) has been suffering from relapsing MS for eight years. In previous relapses, she was treated with corticosteroids, but this has led to psychosis several times. The patient was admitted with brainstem symptoms (double images, crippled paresthesias in the trigeminal area and gross nystagmus with dizziness and nausea). A new focus was found in the brainstem in magnetic resonance imaging. A 5-day infusion treatment with PTX (3 x 200 mg / day i.v.) was carried out. Already on the second day the patient felt a clear improvement in the vertigo symptoms and the double vision. After two days, nystagmus and tendency to fall were no longer clinically detectable. After the infusion therapy, the patient was switched to oral medication of 3 x 400 mg / day. No further relapses have occurred since then (6 months). Before the treatment, the patient had three to four relapses per year.

Example 2:

A female patient (45 years, 58 kg body weight) has been suffering from MS for three years. So far, there have been predominantly sensitive symptoms, which had manifested themselves particularly in unpleasant paraesthesia of the extremities. During another relapse with excruciating, burning sensations on both legs, the patient was treated with 3 x 400 mg PTX / day. The dysaesthesia, which usually lasted for weeks, was reduced to such an extent after only three days that the patient was able to sleep again and to carry out her daily household chores. Here too there is now a 5-month follow-up period during which no further complaints have occurred. Example 3:

In a male patient (36 years, 62 kg body weight), MS has been known for two years. Since then he has had five relapses that were only mild and did not need to be treated. Since the patient has type 1 diabetes mellitus, steroid therapy is extremely risky. Retrobular neuritis is diagnosed if there is a sudden deterioration in vision in the left eye. The fundus copy is inconspicuous. IV infusion therapy with PTX (3 x 300 mg / day) is started immediately. Already the next day the symptoms decrease, the patient can recognize numbers again and the visual acuity is improved from 0.1 to 0.65.

Example 4:

The 48-year-old patient was diagnosed with relapsing MS at the age of 36. In the past two years there has been an accumulation of sensitive and brainstem relapses. The symptoms had only regressed poorly after the last two relapses, and residual conditions with mild ataxia and spastic gait remained. When there was another severe flare-up with complete loss of vision in the right eye, we decided in addition to the high-dose administration of methylprednisolone (1 g per day iv over 3 days) for 4 weeks orally pentoxifylline in a dose of 1200 mg administer. This not only resulted in an almost complete recovery of the visual acuity on the affected eye within 5 days, but also the residual symptoms of the previous relapses improved significantly. At her own request, the patient continued the pentoxifylline treatment (orally) in the dose mentioned above and there was no renewed increase in the period of 8 months to be seen here. Subjectively and objectively, the other symptoms have improved significantly.

Example 5:

In a 23-year-old MS patient with a disease that had existed for two years, a clear hemiplegia on the left had occurred for the first time after several pure sensitive episodes. The initial high-dose treatment with methylprednisolone (1 g i.v. over 3 days) did not lead to any significant improvement in the symptoms. We therefore decided to continue low-dose methylprednisolone orally (reducing 100 mg every other day to 20 mg) and additionally administered 1200 mg of pentoxifylline orally to the patient, which included a dramatic improvement and recovery of walking ability over the next 3 days Tools set. The cortisone dose was then reduced very quickly due to a pathological glucose tolerance while maintaining the pentoxifylline dose. The stability and improvement of the gait pattern that had already occurred could be preserved and in this case the patient also wishes further treatment with pentoxifylline.

Claims

claims

1. Use of pentoxifylline in the treatment of the relapsing or chronically progressive form of MS.

2. Use of pentoxifylline according to claim 1, with a dosage of 0.01 to 6.0 g / day (0.1 to 120 mg per day and kg body weight); preferably 1 to 3 g / day (10 to 60 mg / (day kg)) and most preferably 1.2 to 2.4 g / day (12 to 48 mg / (day kg)).

3. Use of pentoxifylline according to one of the preceding claims 1 or 2 in combination with a corticosteroid.

4. Use of pentoxifylline according to claim 3, wherein the dosage of pentoxifylline 0.01 to 6.0 g / day (0.1 to 120 mg / (day kg)) and the dosage of the corticoids 0.01 to 1000 mg / Day (0.0001 to 20 mg / (day kg)).